Xu Jie, Worrell Roger T, Li Hong C, Barone Sharon L, Petrovic Snezana, Amlal Hassane, Soleimani Manoocher
Division of Nephrology and Hypertension, Department of Medicine, University of Cincinnati, 231 Albert Sabin Way, MSB 259G, Cincinnati, OH 45267-0585, USA.
J Am Soc Nephrol. 2006 Apr;17(4):956-67. doi: 10.1681/ASN.2005111174. Epub 2006 Mar 8.
SLC26A7 is a Cl(-)/HCO(3)(-) exchanger that is expressed on the basolateral membrane and in the cytoplasm of two distinct acid-secreting epithelial cells: The A-intercalated cells in the kidney outer medullary collecting duct and the gastric parietal cells. The intracellular localization of SLC26A7 suggests the possibility of trafficking between cell membrane and intracellular compartments. For testing this hypothesis, full-length human SLC26A7 cDNA was fused with green fluorescence protein and transiently expressed in MDCK epithelial cells. In monolayer cells in isotonic medium, SLC26A7 showed punctate distribution throughout the cytoplasm. However, in medium that was made hypertonic for 16 h, SLC26A7 was detected predominantly in the plasma membrane. The presence of mitogen-activated protein kinase inhibitors blocked the trafficking of SLC26A7 to the plasma membrane. Double-labeling studies demonstrated the localization of SLC26A7 to the transferrin receptor-positive endosomes. A chimera that was composed of the amino terminal fragment of SLC26A7 and the carboxyl terminal fragment of SLC26A1, and a C-terminal-truncated SLC26A7 were retained in the cytoplasm in hypertonicity. In separate studies, SLC26A7 showed predominant localization in plasma membrane in potassium-depleted isotonic medium (0.5 or 2 mEq/L KCl) versus cytoplasmic distribution in normal potassium isotonic medium (4 mEq/L). It is concluded that SLC26A7 is present in endosomes, and its targeting to the basolateral membrane is increased in hypertonicity and potassium depletion. The trafficking to the cell surface suggests novel functional upregulation of SLC26A7 in states that are associated with hypokalemia or increased medullary tonicity. Additional studies are needed to ascertain the role of SLC26A7 in enhanced bicarbonate absorption in outer medullary collecting duct in hypokalemia and in acid-base regulation in conditions that are associated with increased medullary tonicity.
SLC26A7是一种Cl(-)/HCO(3)(-)交换体,表达于两种不同的泌酸上皮细胞的基底外侧膜和细胞质中:肾外髓集合管中的A型闰细胞和胃壁细胞。SLC26A7在细胞内的定位提示了其在细胞膜和细胞内区室之间运输的可能性。为了验证这一假设,将全长人SLC26A7 cDNA与绿色荧光蛋白融合,并在MDCK上皮细胞中瞬时表达。在等渗培养基中的单层细胞中,SLC26A7在整个细胞质中呈点状分布。然而,在高渗16小时的培养基中,SLC26A7主要在质膜中被检测到。丝裂原活化蛋白激酶抑制剂的存在阻断了SLC26A7向质膜的运输。双标记研究表明SLC26A7定位于转铁蛋白受体阳性的内体。由SLC26A7的氨基末端片段和SLC26A1的羧基末端片段组成的嵌合体以及C末端截短的SLC26A7在高渗状态下保留在细胞质中。在单独的研究中,与正常钾等渗培养基(4 mEq/L)中的细胞质分布相比,SLC26A7在低钾等渗培养基(0.5或2 mEq/L KCl)中主要定位于质膜。得出的结论是,SLC26A7存在于内体中,在高渗和低钾状态下其靶向基底外侧膜的能力增强。向细胞表面的运输提示SLC26A7在与低钾血症或髓质张力增加相关的状态下有新的功能上调。需要进一步的研究来确定SLC26A7在低钾血症时外髓集合管中增强的碳酸氢盐吸收以及在与髓质张力增加相关的酸碱调节中的作用。